Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Olema Pharmaceuticals (OLMA)
NASDAQ:OLMA
RESEARCH TOOLSreports
Holding OLMA?
Track your performance easily
OLMA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$8.21 - $16.78
Previous Close$8.72
Volume357.59K
Average Volume (3M)468.12K
Market Cap
$499.64M
Enterprise Value$286.57M
Total Cash (Recent Filing)$214.76M
Total Debt (Recent Filing)$1.70M
Price to Earnings (P/E)―
Beta1.81
Next Earnings
Mar 03, 2025EPS Estimate
-$0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.19
Shares Outstanding57,297,845
10 Day Avg. Volume559,262
30 Day Avg. Volume468,122
Standard Deviation0.28
R-Squared0.11
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)2.51
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-2.29
Forecast
1Y Price Target
$28.40Price Target Upside243.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Olema Pharmaceuticals News
PremiumCompany Announcements
Olema Pharmaceuticals Advances Breast Cancer Treatment Trials
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe combination of palazestrant and ribociclib showed an encouraging clinical benefit rate of 85%, suggesting potential synergy in treatment.
CollaborationsOlema announced an expansion of the clinical collaboration and supply agreement with Novartis, increasing the size of the cohort expansion to approximately 60 advanced ER+ breast cancer patients.
Market OpportunityThe global market opportunity in 2L/3L+ metastatic breast cancer is over $5 billion.
Bears Say
Financial PerformanceOlema has an annualized cash burn of $108 million.
Market SentimentThe short interest in Olema's stock is relatively high, at 17.2% of the float.
Safety ConcernsThe most frequent Grade 3 or higher treatment-related adverse event was neutropenia.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
OLMA FAQ
What was Olema Pharmaceuticals’s price range in the past 12 months?
Olema Pharmaceuticals lowest stock price was $8.21 and its highest was $16.77 in the past 12 months.
What is Olema Pharmaceuticals’s market cap?
Currently, no data Available
When is Olema Pharmaceuticals’s upcoming earnings report date?
Olema Pharmaceuticals’s upcoming earnings report date is Mar 03, 2025 which is in 102 days.
How were Olema Pharmaceuticals’s earnings last quarter?
Olema Pharmaceuticals released its earnings results on Nov 12, 2024. The company reported -$0.6 earnings per share for the quarter, missing the consensus estimate of -$0.571 by -$0.029.
Is Olema Pharmaceuticals overvalued?
According to Wall Street analysts Olema Pharmaceuticals’s price is currently Undervalued.
Does Olema Pharmaceuticals pay dividends?
Olema Pharmaceuticals does not currently pay dividends.
What is Olema Pharmaceuticals’s EPS estimate?
Olema Pharmaceuticals’s EPS estimate is -$0.65.
How many shares outstanding does Olema Pharmaceuticals have?
Olema Pharmaceuticals has 57,297,844 shares outstanding.
What happened to Olema Pharmaceuticals’s price movement after its last earnings report?
Olema Pharmaceuticals reported an EPS of -$0.6 in its last earnings report, missing expectations of -$0.571. Following the earnings report the stock price went down -0.52%.
Which hedge fund is a major shareholder of Olema Pharmaceuticals?
Among the largest hedge funds holding Olema Pharmaceuticals’s share is Woodline Partners LP. It holds Olema Pharmaceuticals’s shares valued at 10M.
---
Olema Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.40 (243.00% Upside)
$28.40 (243.00% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.19%
12-Months-Change
Fundamentals
Return on Equity
-51.76%
Trailing 12-Months
Asset Growth
-21.39%
Trailing 12-Months
Company Description
Olema Pharmaceuticals
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250.
---
OLMA Stock 12 Month Forecast
Average Price Target
$28.40
▲(243.00% Upside)
Technical Analysis
Best Analysts Covering OLMA
1 Year
1 Year Success Rate
9/17 ratings generated profit
1 Year Average Return
+89.97%
reiterated a buy rating 9 days ago
Copying Emily Bodnar's trades and holding each position for 1 Year would result in 52.94% of your transactions generating a profit, with an average return of +89.97% per trade.
---